Cited by 263Telomeres, Telomerase, and SenescenceBone Metabolism and DiseasesGenetics, Aging, and Longevity in Model Organisms

Cellular senescence in bone

Open access
Farr, Joshua N., Khosla, Sundeep·2019·Bone

Abstract

Cellular senescence refers to a process induced by various types of stress that causes irreversible cell cycle arrest and distinct cellular alterations, including profound changes in gene expression, metabolism, and chromatin organization as well as activation/reinforcement of anti-apoptotic pathways and development of a pro-inflammatory secretome or senescence-associated secretory phenotype (SASP). However, because of challenges and technical limitations in identifying and characterizing senescent cells in living organisms, only recently have some of the diverse in vivo roles of these unique cells been discovered. New findings indicate that senescent cells and their SASP can have acute beneficial functions, such as in tissue regeneration and wound healing. However, in contrast, when senescent cells accumulate in excess chronically at sites of pathology or in old tissues they drive multiple age-associated chronic diseases. Senotherapeutics that selectively eliminate senescent cells ("senolytics") or inhibit their detrimental SASP ("senomorphics") have been developed and tested in aged preclinical models. These studies have established that targeting senescence is a powerful anti-aging strategy to improve "healthspan" - i.e., the healthy period of life free of chronic disease. The roles of senescence in mediating age-related bone loss have been a recent focus of rigorous investigation. Studies in mice and humans demonstrate that with aging, at least a subset of most cell types in the bone microenvironment become senescent and develop a heterogeneous SASP. Furthermore, age-related bone loss can be alleviated in old mice, with apparent advantages over anti-resorptive therapy, by reducing the senescent cell burden genetically or pharmacologically with the first class of senolytics or a senomorphic. Collectively, these findings point to targeting senescence as a transformational strategy to extend healthspan, therefore providing strong rationale for identifying and optimizing senotherapeutics to alleviate multiple chronic diseases of aging, including osteoporosis, and set the stage for translating senotherapeutics to humans, with clinical trials currently ongoing.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bone.2019.01.015

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clearing senescent osteocytes increases bone strength.

    “their clearance increased bone strength130”

    From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [130]

    The 'Causal role of senescent cells in mediating age-related bone loss' section reports that treatment reduced senescent osteocytes and that eliminating senescent cells improved bone strength in old mice. But the treatment eliminated senescent cells systemically and locally, not osteocytes specifically, so the paper does not establish that clearing senescent osteocytes caused the strength increase. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Senescent osteocytes with high p16 are associated with age-related bone loss in mice.

    “Senescent osteocytes that express p16 at high levels have been associated with age-related bone loss in mice”

    From Telomere dysfunction in ageing and age-related diseases (2022) · cites this paper as [130]

  • The early proinflammatory condition in regenerating tissues mimics the senescence-associated secretory phenotype (SASP); it appears beneficial if intermittent but causes pathology if chronically active.

    “Not only is this condition in common for regenerating tissues in the early phase, but it also somehow mimics the senescence-associated secretory phenotype (SASP) of presenescent and senescent cells. It appears to be beneficial if intermittent, but it causes pathology if chronically active.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Farr, J. N., & Khosla, S.
Affiliations
Mayo Clinic (US)
Corresponding author
  • Farr, Joshua N.
  • Khosla, Sundeep
Venue
Bone
Publisher
Elsevier BV
Published
2019-04
Volume
121
Pages
121-133
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
OpenAlex
W2910083643
Cited by
263
References
113
Citations by year
2026: 43 · 2025: 46 · 2024: 46 · 2023: 41 · 2022: 33 · 2021: 17 · 2020: 30 · 2019: 7
FWCI
2.56
Type
journal article
Language
en
Open access
Locations
  • Bone (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (R01 AG048792, P01 AG004875, R01 AR027065, K01 AR070241)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
Keywords
cellular senescence, senescence-associated secretory phenotype, bone aging, age-related bone loss, osteoporosis, senolytics, senomorphics, senotherapeutics, healthspan, bone microenvironment, tissue regeneration
MeSH terms
Aging, Animals, Bone and Bones, Humans, Osteocytes, Osteoporosis, Cellular Senescence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review